Kulli Barrett, MD
Nephrology · Portsmouth, NHNPI 1437140209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $77 of the $122 with a category attached, or 63.4%. Calliditas Therapeutics US Inc. accounts for 63.4% of it on its own, with 3 other manufacturers making up the rest. 2024 is the largest year on record at $77, 6.2 times the $12 reported in 2021. That places this record below the midpoint for nephrology clinicians in NH, where the typical reported total is $118.
Across 4 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$77
- Amgen$20
- Otsuka America Pharmaceutical, Inc.$12
- Vifor Pharma, Inc.$12
What the payments were for
- Food & beverage$7763%
- Education$4537%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 1 | $77 |
| Amgen | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Vifor Pharma, Inc. | 1 | $12 |
How this compares
$122 in reported general payments places this provider in the 50th percentile of 33 nephrology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 13 | $64,934 |
| JardianceEmpagliflozin | 25 | $18,018 |
| LokelmaSodium Zirconium Cyclosilicate | 25 | $17,316 |
| Lanthanum Carbonate | 20 | $17,164 |
| Sevelamer Carbonate | 155 | $15,502 |
| AuryxiaFerric Citrate | 13 | $14,013 |
| FarxigaDapagliflozin Propanediol | 13 | $10,416 |
| Potassium Citrate ErPotassium Citrate | 25 | $4,292 |
| Midodrine Hcl | 54 | $2,921 |
| Labetalol Hcl | 22 | $1,360 |
| Furosemide | 136 | $1,048 |
| Losartan Potassium | 117 | $981 |
| Terazosin Hcl | 38 | $640 |
| Amlodipine Besylate | 107 | $629 |
| Allopurinol | 27 | $450 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Portsmouth
- Sucharit JoshiPortsmouth$6K
- Michael DanielskiPortsmouth$142
- Shiv KumarPortsmouth$109
- Satyaki ChakrabartyPortsmouth$77
- Naresh MattaPortsmouth$37
- Ana StankovicSalem$66K
- Elizabeth BrandtLebanon$41K
- John Patrick SiaManchester$12K
- Yishu HanConcord$1K
- Shaikh HoqueNashua$740
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.